

Bibliography

- [1] Tripathi, K. D. (2020). *Essentials of medical pharmacology for dentistry*. (8th ed.). Jaypee Brothers Medical Publishers.
- [2] Lorian, V. (2005). *Antibiotics in laboratory medicine*. Lippincott Williams & Wilkins.
- [3] Harvey, R. A., & Ferrier, D. R. (2012). *Lippincott's illustrated reviews. Pharmacology*, 526.
- [4] Bryskier, A. (2005). *Antimicrobial agents: antibacterials and antifungals*. ASM press.
- [5] Li, G., Jing, X., Zhang, P., & De Clercq, E. (2021). *Antiviral classification. Encyclopedia of Virology*, 121.
- [6] Ullah, H., & Ali, S. (2017). *Classification of anti-bacterial agents and their functions. Antibacterial Agents*, 10, 1–10.
- [7] Finch, R. G., Greenwood, D., Whitley, R. J., & Norrby, S. R. (2010). *Antibiotic and chemotherapy e-book*. Elsevier Health Sciences.
- [8] Basak, A., Chakraborty, R., & Mandal, S. M. (2016). *Recent trends in antifungal agents and antifungal therapy*. Springer.
- [9] Tang, H. (2019). *Hepatitis B Virus Infection: Molecular Virology to Antiviral Drugs (Vol. 1179)*. Springer.
- [10] Zhan, P., Pannecouque, C., De Clercq, E., & Liu, X. (2016). *Anti-HIV drug discovery and development: current innovations and future trends: miniperspective. Journal of Medicinal Chemistry*, 59(7), 2849–2878.
- [11] de Béthune, M.-P. (2010). *Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989–2009)*. *Antiviral Research*, 85(1), 75–90.
- [12] Wang, Y., De Clercq, E., & Li, G. (2019). *Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment. Expert Opinion on Drug Metabolism & Toxicology*, 15(10), 813–829. <https://doi.org/10.1080/17425255.2019.1673367>
- [13] Zhuang, C., Pannecouque, C., De Clercq, E., & Chen, F. (2020). *Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty*

- years. *Acta Pharmaceutica Sinica B*, 10(6), 961–978.
<https://doi.org/10.1016/j.apsb.2019.11.010>
- [14] Singh, R. (2013). HPLC method development and validation-an overview. *Journal of Pharmaceutical Education & Research*, 4(1).
- [15] Marson, B. M., Concentino, V., Junkert, A. M., Fachi, M. M., Vilhena, R. O., & Pontarolo, R. (2020). Validation of analytical methods in a pharmaceutical quality system: An overview focused on HPLC methods. *Química Nova*, 43, 1190–1203.
- [16] Swartz, M. E., & Krull, I. S. (2018). *Analytical method development and validation*. CRC press.
- [17] Gupta, V., Jain, A. D. K. J., Gill, N. S., & Guptan, K. (2012). Development and validation of HPLC method-a review. *International Research Journal of Pharmaceutical and Applied Sciences*, 2(4), 17–25.
- [18] Riley, C. M., Rosanske, T. W., & Reid, G. L. (2020). *Specification of drug substances and products: development and validation of analytical methods*. Elsevier.
- [19] Bakshi, M., & Singh, S. (2002). Development of validated stability-indicating assay methods—critical review. *Journal of Pharmaceutical and Biomedical Analysis*, 28(6), 1011–1040.
- [20] Singh, D. K., Singh, S., & Bajaj, S. (2018). Regulatory guidelines on stability testing and trending of requirements. In *Methods for Stability Testing of Pharmaceuticals* (pp. 1–30). Springer.
- [21] Singh, R. (2013). HPLC method development and validation-an overview. *Journal of Pharmaceutical Education & Research*, 4(1).
- [22] Singh, S., Junwal, M., Modhe, G., Tiwari, H., Kurmi, M., Parashar, N., & Sidduri, P. (2013). Forced degradation studies to assess the stability of drugs and products. *TrAC Trends in Analytical Chemistry*, 49, 71–88.
- [23] Blessy, M., Patel, R. D., Prajapati, P. N., & Agrawal, Y. K. (2014). Development of forced degradation and stability indicating studies of drugs- A review. *Journal of Pharmaceutical Analysis*, 4(3), 159–165.
<https://doi.org/10.1016/j.jpha.2013.09.003>

- [24] Singh, R., & Rehman, Z. U. (2012). Current trends in forced degradation study for pharmaceutical product development. *Journal of Pharmaceutical Education and Research*, 3(1), 54.
- [25] Sehrawat, R., Maithani, M., & Singh, R. (2010). Regulatory aspects in development of stability-indicating methods: a review. *Chromatographia*, 72(1), 1–6.
- [26] Ojha, A., & Bhargava, S. (2022). International Council for Harmonisation (ICH) guidelines. In *Regulatory Affairs in the Pharmaceutical Industry* (pp. 47–74). Elsevier.
- [27] Guideline, I. C. H. H. T. (2005). Validation of analytical procedures: text and methodology. *Q2 (R1)*, 1(20), 5.
- [28] Perkampus, H.-H. (2013). *UV-VIS Spectroscopy and its Applications*. Springer Science & Business Media.
- [29] Görög, S. (2018). *Ultraviolet-visible spectrophotometry in pharmaceutical analysis*. CRC press.
- [30] Watson, D. G. (2020). *Pharmaceutical analysis E-book: a textbook for pharmacy students and pharmaceutical chemists*. Elsevier Health Sciences.
- [31] Passos, M. L. C., & Saraiva, M. L. M. F. S. (2019). Detection in UV-visible spectrophotometry: Detectors, detection systems, and detection strategies. *Measurement hplc*, 135, 896–904.
- [32] Ermer, J., & Miller, J. H. M. (2006). *Method validation in pharmaceutical analysis: A guide to best practice*. John Wiley & Sons.
- [33] Dong, M. W. (2019). *HPLC and UHPLC for Practicing Scientists*. John Wiley & Sons.
- [34] Akash, M. S. H., & Rehman, K. (2020). High performance liquid chromatography. In *Essentials of pharmaceutical analysis* (pp. 175–184). Springer.
- [35] Bonfilio, R., Cazedey, E. C. L., Araújo, M. B. de, & Nunes Salgado, H. R. (2012). Analytical validation of quantitative high-performance liquid chromatographic methods in pharmaceutical analysis: a practical approach. *Critical Reviews in Analytical Chemistry*, 42(1), 87–100.

- [36] Kazusaki, M., Ueda, S., Takeuchi, N., & Ohgami, Y. (2012). Validation of analytical procedures by highperformance liquid chromatography for pharmaceutical analysis. *Chromatography*, 33(2), 65–73.
- [37] Bunaciu, A. A., Aboul-Enein, H. Y., & Fleschin, S. (2010). Application of Fourier transform infrared spectrophotometry in pharmaceutical drugs analysis. *Applied Spectroscopy Reviews*, 45(3), 206–219.
- [38] Dressman, J. B., & Krämer, J. (2005). *Pharmaceutical dissolution testing*. Taylor & Francis Boca Raton, FL:
- [39] Fotaki, N., & Klein, S. (2019). *In Vitro Drug Release Testing of Special Dosage Forms*. John Wiley & Sons.
- [40] Cohen, J. L., Hubert, B. B., Leeson, L. J., Rhodes, C. T., Robinson, J. R., Roseman, T. J., & Shefter, E. (1990). The development of USP dissolution and drug release standards. *Pharmaceutical Research*, 7(10), 983–987.
- [41] Gray, V. A., & Rosanske, T. W. (2020). Dissolution. In *Specification of Drug Substances and Products* (pp. 481–503). Elsevier.
- [42] Adhao, V. S., Chaudhari, S. R., Ambhore, J. P., Sangolkar, S., Thenge, R. R., Cheke, R. S., & Patil, A. S. (2021). Reverse phase-liquid chromatography assisted protocol for simultaneous determination of lamivudine and tenofovir disoproxil fumarate in combined medication used to control HIV infection: an investigative approach. *Future Journal of Pharmaceutical Sciences*, 7(1), 90. <https://doi.org/10.1186/s43094-021-00233-3>
- [43] Bedse, G., Kumar, V., & Singh, S. (2009). Study of forced decomposition behavior of lamivudine using LC, LC–MS/TOF and MSn. *Journal of Pharmaceutical and Biomedical Analysis*, 49(1), 55–63. <https://doi.org/10.1016/j.jpba.2008.10.002>
- [44] Bhavsar, D. S., Patel, B. N., & Patel, C. N. (2012). RP-HPLC method for simultaneous estimation of tenofovir disoproxil fumarate, lamivudine, and efavirenz in combined tablet dosage form. *Pharmaceutical Methods*, 3(2), 73–78. <https://doi.org/10.4103/2229-4708.103876>
- [45] Chengalva, P., & Kuchana, M. (2020). Development and Validation of Ultra Performance Liquid Chromatographic Method for the Simultaneous Estimation of Lamivudine, Tenofovir Disoproxil Fumarate, Doravirine and Efavirenz in Bulk and Pharmaceutical Formulations. *Indian Journal of*

- Pharmaceutical Sciences, 82(6). <https://doi.org/10.36468/pharmaceutical-sciences.732>.
- [46] Dubey, S., & Duggirala, M. (2018). Simultaneous Estimation Of Lamivudine, Abacavir And Dolutegravir By Uplc Method. *International Journal of Applied Pharmaceutics*, 10(1), 46. <https://doi.org/10.22159/ijap.2018v10i1.21156>
- [47] Godela, R., & G, S. (2020). An effective stability indicating RP-HPLC method for simultaneous estimation of Dolutegravir and Lamivudine in bulk and their tablet dosage form. *Future Journal of Pharmaceutical Sciences*, 6(1), 9. <https://doi.org/10.1186/s43094-020-00026-0>
- [48] Golla, V. M., Kurmi, M., Shaik, K., & Singh, S. (2016). Stability behaviour of antiretroviral drugs and their combinations. 4: Characterization of degradation products of tenofovir alafenamide fumarate and comparison of its degradation and stability behaviour with tenofovir disoproxil fumarate. *Journal of Pharmaceutical and Biomedical Analysis*, 131, 146–155. <https://doi.org/10.1016/j.jpba.2016.08.022>
- [49] Gorja, A., & Bandla, J. (2013). Method Development And Validation For The Simultaneous Estimation Of Lamivudine And Tenofovir Disoproxil Fumarate In Pharmaceutical Dosage Forms By RP-HPLC, 125, 113-119.
- [50] Kurmi, M., Kushwah, B. S., Sahu, A., Narayanam, M., & Singh, S. (2016). Stability behaviour of antiretroviral drugs and their combinations. 2: Characterization of interaction products of lamivudine and tenofovir disoproxil fumarate by mass and NMR spectrometry. *Journal of Pharmaceutical and Biomedical Analysis*, 125, 245–259. <https://doi.org/10.1016/j.jpba.2016.03.039>
- [51] Kurmi, M., Sahu, A., Ladumor, M. K., Kumar Bansal, A., & Singh, S. (2019). Stability behaviour of antiretroviral drugs and their combinations. 9: Identification of incompatible excipients. *Journal of Pharmaceutical and Biomedical Analysis*, 166, 174–182. <https://doi.org/10.1016/j.jpba.2019.01.009>
- [52] Kurmi, M., & Singh, S. (2017). Stability behavior of antiretroviral drugs and their combinations. 7: Comparative degradation pathways of lamivudine and emtricitabine and explanation to their differential degradation behavior by

- density functional theory. *Journal of Pharmaceutical and Biomedical Analysis*, 142, 155–161. <https://doi.org/10.1016/j.jpba.2017.04.034>
- [53] Murali Krishna, M. V. V. N., Rao, S. V., & Venugopal, N. V. S. (2018). Forced Degradation Study for Tenofovir DF, Lamivudine and Efavirenz in Triple Combination Anti-Retroviral Tablets and Development of Validated Stability Indicating Assay Method by UPLC. *Current Pharmaceutical Analysis*, 15(1), 82–94. <https://doi.org/10.2174/1573412913666171120163959>
- [54] Nihila, K. (2021). Method Development And Validation For Simultaneous Estimation Of Lamivudine, Dolutegravir And Tenofovir Disoproxil Fumarate In Bulk And Pharmaceutical Dosage Form Using Rp-Hplc And Its Application To In-Vitro Dissolution Study. *Journal of Medical Pharmaceutical and Allied Sciences*, 10(4), 3202–3207. <https://doi.org/10.22270/jmpas.V10I4.1165>
- [55] R, S., T, S., D, G., & M, T. (2021). Analytical Method Development and Validation of Stability Indicating assay method of analysis for Dolutegravir/Lamivudine/Tenofovir Disoproxil Fumarate tablets using High Performance Liquid Chromatography. *Research Journal of Pharmacy and Technology*, 2434–2439. <https://doi.org/10.52711/0974-360X.2021.00428>
- [56] S., M., & P., S. (2021). Bioanalytical Method Development and Validation of Doravirine, Lamavudine and Tenofovir Disoproxil Fumarate using HPLC in Human Plasma. *Research Journal of Pharmacy and Technology*, 4087–4091. <https://doi.org/10.52711/0974-360X.2021.00708>
- [57] Sheng, H., Lexa, K. W., Zhang, L.-K., Yang, R.-S., Wright, T. J., Sherry, B. D., Helmy, R., & Martin, G. E. (2017). Unusual (+/-)-electrospray ionization induced fragmentation: Structural elucidation of an in-process synthetic intermediate of doravirine (MK-1439) using liquid chromatography/high-resolution tandem mass spectrometry and two-dimensional nuclear magnetic r. *Rapid Communications in Mass Spectrometry*, 31(8), 719–727. <https://doi.org/10.1002/rcm.7833>
- [58] Sireesha, D. (2016). Analytical Method Development and Validation for the Simultaneous Estimation of Lamivudine and Tenofovir Disoproxil Fumarate by RP-HPLC Method. *MOJ Proteomics & Bioinformatics*, 4(5). <https://doi.org/10.15406/mojpb.2016.04.00134>

- [59] Suen, L., Wang, C., Hunter, D., Mitchell, H., Converso, A., & ElMarrouni, A. (2018). Synthesis of HIV NNRTI Doravirine Analogues via Visible-Light Photoredox Decarboxylative Cross-Coupling. *Synthesis*, 50(16), 3177–3186. <https://doi.org/10.1055/s-0037-1610155>
- [60] Sumanth, K. S., Rao, A. S., & Shankar, D. G. (2018). A new stability indicating RP-HPLC method development and validation for simultaneous estimation of emtricitabine and tenofovir with degradation kinetics. *Asian Journal of Research in Chemistry*, 11(3), 569. <https://doi.org/10.5958/0974-4150.2018.00102.5>
- [61] Venkatesan, S., & Kannappan, N. (2014). Simultaneous Spectrophotometric Method for Determination of Emtricitabine and Tenofovir Disoproxil Fumarate in Three-Component Tablet Formulation Containing Rilpivirine Hydrochloride. *International Scholarly Research Notices*, 2014, 1–8. <https://doi.org/10.1155/2014/541727>
- [62] Venkatesan, S., Kannappan, N., & Mannemala, S. S. (2014). Stability-Indicating HPLC Method for the Simultaneous Determination of HIV Tablet Containing Emtricitabine, Tenofovir Disoproxil Fumarate, and Rilpivirine Hydrochloride in Pharmaceutical Dosage Forms. *International Scholarly Research Notices*, 2014, 1–9. <https://doi.org/10.1155/2014/849149>
- [63] Zhang, L.-K., Yang, R., Sheng, H., et al., (2016). Characterization of impurities of HIV NNRTI Doravirine by UHPLC-high resolution MS and tandem MS analysis. *Journal of Mass Spectrometry*, 51(10), 959–968. <https://doi.org/10.1002/jms.3807>
- [64] Courlet, P., Alves Saldanha, S., Cavassini, M., et al., (2020). Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HI. *Journal of Mass Spectrometry*, 55(6), e4506. <https://doi.org/10.1002/jms.4506>
- [65] Date, A. A., Shibata, A., Bruck, P., & Destache, C. J. (2015). Development and validation of a simple and isocratic reversed-phase HPLC method for the determination of rilpivirine from tablets, nanoparticles and HeLa cell lysates. *Biomedical Chromatography*, 29(5), 709–715.

- [66] Enggi, C. K., Isa, H. T., Wijaya, S., et al., (2022). Validation of spectrophotometric method to quantify cabotegravir in simulated vaginal fluid and porcine vaginal tissue in ex vivo permeation and retention studies from thermosensitive and mucoadhesive gels. *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy*, 267, 120600.
- [67] Ghosh, S., Bomma, S., Prasanna, et al., (2013). Method development and validation of rilpivirine in bulk and tablet doses form by RP-HPLC method. *Research Journal of Pharmacy and Technology*, 6(3), IV.
- [68] Hobson, J. J., Al-Khouja, A., Curley, P., et al., (2019). Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies. *Nature Communications*, 10(1), 1–10.
- [69] Karunakaran, D., Simpson, J. T., Bryndza-Tfaily, et al., (2021). Design and testing of a cabotegravir implant for HIV prevention. *Journal of Controlled Release*, 330, 658–668.
- [70] Kovač, L., Časar, Z., Trdan Luštin, T., & Roškar, R. (2022). Development of an Analytical Method for Determination of Related Substances and Degradation Products of Cabotegravir Using Analytical Quality by Design Principles. *ACS Omega*, 7(10), 8896–8905.
- [71] Letendre, S. L., Mills, A., Hagins, D., et al., (2020). Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults. *Journal of Antimicrobial Chemotherapy*, 75(3), 648–655. <https://doi.org/10.1093/jac/dkz504>
- [72] Mamata, D., & Naik Sapavatu, S. (2022). RP-HPLC method for swift analysis of Lamivudine and Dolutegravir in formulation, stability studies. *Asian Journal of Pharmaceutical Analysis*, 105–110. <https://doi.org/10.52711/2231-5675.2022.00019>
- [73] Merli, M., Galli, L., Marinaro, L., et al., (2017). Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis. *Journal of Antimicrobial Chemotherapy*, 72(3), 812–815.
- [74] Ramöller, I. K., Abbate, M. T. A., Vora, et al., (2022). HPLC-MS method for simultaneous quantification of the antiretroviral agents rilpivirine and

- cabotegravir in rat plasma and tissues. *Journal of Pharmaceutical and Biomedical Analysis*, 213, 114698. <https://doi.org/10.1016/j.jpba.2022.114698>
- [75] Ulianova, Y., Ermolenko, Y., Trukhan, V., et al., (2017). Development of a Long-Acting Injectable Formulation of Rilpivirine Based On PLGA Microspheres. *Evaluation*, 100, 3.
- [76] Veeraswami, B., & Naveen, V. M. K. (2019). Development and Validation of RP-HPLC Method for the Estimation of Dolutegravir and Rilpivirine in Bulk and Pharmaceutical Dosage Form and Its Application to Rat Plasma. *Development*, 12(2).
- [77] Vejjendla, A., Talari, S., Moturu, R., et al., (2021). Method development and validation for Cabotegravir and Rilpivirine by using HPLC and its degradants are characterized by LCMS and FTIR. *Future Journal of Pharmaceutical Sciences*, 7(1), 226. <https://doi.org/10.1186/s43094-021-00355-8>
- [78] Zang, H., Fofana, J., Nodder, S. B., et al., (2022). Characterizing Lipid-Coated Mesoporous Silica Nanoparticles as CD147 Binding Delivery System for Rilpivirine and Cabotegravir. *Advanced NanoBiomed Research*, 2100157.
- [79] Grégoire, M., Deslandes, G., Renaud, C., et al., (2014). A liquid chromatography–tandem mass spectrometry assay for quantification of rilpivirine and dolutegravir in human plasma. *Journal of Chromatography B*, 971, 1–9. <https://doi.org/10.1016/j.jchromb.2014.09.006>
- [80] Jain, P., Thota, A., Saini, P. K., et al., (2022). Comprehensive Review on Different Analytical Techniques for HIV 1-Integrase Inhibitors: Raltegravir, Dolutegravir, Elvitegravir and Bictegravir. *Critical Reviews in Analytical Chemistry*, 1–15.
- [81] Mallikarjuna Rao, N., Gowri Sankar, D. (2015). Development and validation of stability-indicating HPLC method for simultaneous determination of Lamivudine, Tenofovir, and Dolutegravir in bulk and their tablet dosage form. *Future Journal of Pharmaceutical Sciences*, 1(2), 73–77. <https://doi.org/10.1016/j.fjps.2015.11.002>
- [82] Mamata, D., & Naik Sapavatu, S. (2022). RP-HPLC method for swift analysis of Lamivudine and Dolutegravir in formulation, stability studies. *Asian Journal of Pharmaceutical Analysis*, 105–110. <https://doi.org/10.52711/2231-5675.2022.00019>

- [83] Nagasarapu, M. R., & Dannana, G. S. (2016). Development and Validation of Stability-Indicating HPLC-DAD Method for Simultaneous Determination of Emtricitabine, Elvitegravir, Cobicistat and Tenofovir in Their Tablet Dosage Forms. *Indian Journal of Pharmaceutical Education and Research*, 50(1), 205–211. <https://doi.org/10.5530/ijper.50.1.25>
- [84] Noorbasha, K., & Nurbasha, S. (2020). A new validated stability-indicating RP-HPLC method for simultaneous quantification of dolutegravir and lamivudine in bulk and pharmaceutical dosage form. *Future Journal of Pharmaceutical Sciences*, 6(1), 39. <https://doi.org/10.1186/s43094-020-00060-y>
- [85] Patel, S. H., Ismaiel, O. A., Mylott, et al., (2019). Simultaneous determination of intracellular concentrations of tenofovir, emtricitabine, and dolutegravir in human brain microvascular endothelial cells using liquid chromatography-tandem mass spectrometry (LC-MS/MS). *Analytica Chimica Acta*, 1056, 79–87. <https://doi.org/10.1016/j.aca.2019.01.015>
- [86] Prathipati, P. K., Mandal, S., Destache, C. J. (2016). Simultaneous quantification of tenofovir, emtricitabine, rilpivirine, elvitegravir and dolutegravir in mouse biological matrices by LC–MS/MS and its application to a pharmacokinetic study. *Journal of Pharmaceutical and Biomedical Analysis*, 129, 473–481. <https://doi.org/10.1016/j.jpba.2016.07.040>
- [87] Rathod, S. M., Patel, P. U. (2020). Development and Validation of RP – HPLC Method for Estimation of Lamivudine and Dolutegravir Sodium in Synthetic Mixture. *Research Journal of Pharmacy and Technology*, 13(6), 2864. <https://doi.org/10.5958/0974-360X.2020.00510.7>
- [88] Simiele, M., Ariaudo, A., De Nicolò, A., et al., (2017). UPLC–MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma. *Journal of Pharmaceutical and Biomedical Analysis*, 138, 223–230. <https://doi.org/10.1016/j.jpba.2017.02.002>
- [89] Tamilarasan, S., Malathi, S. (2021). Analytical Method Development and Validation for the Estimation of Dolutegravir and Lamivudine in Bulk Form

- by RP-HPLC. *Journal of Pharmaceutical Sciences and Research*, 13(4), 227–231.
- [90] Zheng, Y., Aboura, R., Boujaafar, S., et al., (2020). HPLC-MS/MS method for the simultaneous quantification of dolutegravir, elvitegravir, rilpivirine, darunavir, ritonavir, raltegravir and raltegravir- β -d-glucuronide in human plasma. *Journal of Pharmaceutical and Biomedical Analysis*, 182, 113119. <https://doi.org/10.1016/j.jpba.2020.113119>
- [91] Filali-Ansary, A., Augé, C., Abgrall, A., et al., (2016). A DBS method for quantitation of the new oral trypanocidal drug fexinidazole and its active metabolites. *Bioanalysis*, 8(19), 2045–2063.
- [92] Mesu, V. K., Kalonji, W. M., Bardonneau, C., et al., (2018). Oral fexinidazole for late-stage African *Trypanosoma brucei gambiense* trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. *The Lancet*, 391(10116), 144–154. [https://doi.org/10.1016/S0140-6736\(17\)32758-7](https://doi.org/10.1016/S0140-6736(17)32758-7)
- [93] Pelfrene, E., Harvey Allchurch, M., Ntamabyaliro, N., et al., (2019). The European Medicines Agency's scientific opinion on oral fexinidazole for human African trypanosomiasis. *PLoS Neglected Tropical Diseases*, 13(6), e0007381.
- [94] Pollastri, M. P. (2018). Fexinidazole: A New Drug for African Sleeping Sickness on the Horizon. *Trends in Parasitology*, 34(3), 178–179. <https://doi.org/10.1016/j.pt.2017.12.002>
- [95] Sravani, R. R., Sowmya, P. S. (2022). Quantitative Determination Of Fexinidazole In Bulk And Tablet Dosage Form By Rp-Hplc. *World Journal Of Pharmacy And Pharmaceutical Sciences*, 11(6), 1882–1891. https://storage.googleapis.com/journal-uploads/wjpps/article_issue/1654256097.pdf
- [96] Torreele, E., Bourdin Trunz, B., Tweats, D., et al., (2010). Fexinidazole – A New Oral Nitroimidazole Drug Candidate Entering Clinical Development for the Treatment of Sleeping Sickness. *PLoS Neglected Tropical Diseases*, 4(12), e923. <https://doi.org/10.1371/journal.pntd.0000923>
- [97] Amara, A., Penchala, S. D., Else, L., et al., (2021). The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite β -d-N4-hydroxycytidine in human plasma

- and saliva. *Journal of Pharmaceutical and Biomedical Analysis*, 206, 114356.
<https://doi.org/10.1016/j.jpba.2021.114356>
- [98] Attia, M. S. (2022). RP-HPLC-UV Method Development and Validation for the Determination of Molnupiravir in Bulk Powder and Pharmaceutical Formulation. *Egyptian Journal of Chemistry*.
- [99] Burke, A., Birmingham, W., Zhuo, Y., et al., (2021). A biocatalytic approach to a key intermediate for the synthesis of the COVID-19 experimental drug Molnupiravir.
- [100] Gopalsamuthiram, V., Kadam, A. L., Noble, J. K., et al., (2021). Toward a Practical, Nonenzymatic Process for Investigational COVID-19 Antiviral Molnupiravir from Cytidine: Supply-Centered Synthesis. *Organic Process Research & Development*, 25(12), 2679–2685.
<https://doi.org/10.1021/acs.oprd.1c00219>
- [101] Jain, S., Giri, S., Sharma, N., Shah, R. P. (2022). LC and LC-HRMS studies on stability behavior of molnupiravir an anti-COVID 19 drug. *Journal of Liquid Chromatography & Related Technologies*, 1–10.
<https://doi.org/10.1080/10826076.2022.2063331>
- [102] M. Bindu, Kumaraswamy G., Swapna Vemireddy., Sashmitha S., et al., (2022). A validated stability indicating RP-HPLC method for the determination of molnupiravir in pharmaceutical dosage form. *World Journal of Advanced Research and Reviews*, 15(1), 580–590.
<https://doi.org/10.30574/wjarr.2022.15.1.0720>
- [103] Moneim, A., Kamal, M., Hamdy, M. (2022). Simple Green Spectrophotometric & Chromatographic Assay of the Oral Antiviral Treatment of COVID-19: Molnupiravir-EIDD-2801. *Egyptian Journal of Chemistry*.
- [104] Reçber, T., Timur, S. S., Erdoğan Kablan, S., et al., (2022). A stability indicating RP-HPLC method for determination of the COVID-19 drug molnupiravir applied using nanoformulations in permeability studies. *Journal of Pharmaceutical and Biomedical Analysis*, 214, 114693.
<https://doi.org/10.1016/j.jpba.2022.114693>
- [105] Saraya, R. E., Deeb, S. El, Salman, B. I., et al., (2022). Highly sensitive high-performance thin-layer chromatography method for the simultaneous

- determination of molnupiravir, favipiravir, and ritonavir in pure forms and pharmaceutical formulations. *Journal of Separation Science*, 45(14), 2582–2590. <https://doi.org/10.1002/jssc.202200178>
- [106] Sharaf, Y. A., El Deeb, S., Ibrahim, A. E., et al., (2022). Two Green Micellar HPLC and Mathematically Assisted UV Spectroscopic Methods for the Simultaneous Determination of Molnupiravir and Favipiravir as a Novel Combined COVID-19 Antiviral Regimen. *Molecules*, 27(7), 2330. <https://doi.org/10.3390/molecules27072330>
- [107] Aktaş, A. H., & Sarıdağ, A. M. (2017). Liquid Chromatographic–Chemometric Techniques for the Simultaneous HPLC Determination of Lansoprazole, Amoxicillin and Clarithromycin in Commercial Preparation. *Journal of Chromatographic Science*, 55(8), 798–804. <https://doi.org/10.1093/chromsci/bmx039>
- [108] Al-Qahtani, S. D., Al-nami, S. Y. (2021). Copper oxide nanopowder modified carbon paste electrode for the voltammetric assay of vonoprazan. *Arabian Journal of Chemistry*, 14(8), 103254. <https://doi.org/10.1016/j.arabjc.2021.103254>
- [109] Gülfen, M., Canbaz, Y., Özdemir, A. (2020). Simultaneous determination of amoxicillin, lansoprazole, and levofloxacin in pharmaceuticals by HPLC with UV–Vis detector. *Journal of Analysis and Testing*, 4(1), 45–53.
- [110] Hassib, S. T., Taha, E. A., Sharf, M. G., et al., (2022). RP-HPLC–DAD Method Development and Validation for Simultaneous Determination of Lansoprazole, Tinidazole, Amoxicillin, and Naproxen in Their Raw Materials and Combined Dosage Form: DOE Approach for Optimization of the Proposed Method. *Journal of AOAC International*, 105(3), 675–687.
- [111] Lal, B., Jaimini, M., Kapoor, D. U. (2021). Development And Validation Of A Rp-Hplc Method For The Simultaneous Estimation Of Clarithromycin, Tinidazole And Lansoprazole In Fixed Dose Combinations. *Tropical Journal of Pharmaceutical and Life Sciences*, 8(4), 1–10.
- [112] Löffler, D., Ternes, T. A. (2003). Determination of acidic pharmaceuticals, antibiotics and ivermectin in river sediment using liquid chromatography–tandem mass spectrometry. *Journal of Chromatography A*, 1021(1–2), 133–144. <https://doi.org/10.1016/j.chroma.2003.08.089>

- [113] Luo, Z., Liu, A., Liu, Y., Wang, G., et al., (2018). Development of a stability-indicating HPLC method for simultaneous determination of ten related substances in vonoprazan fumarate drug substance. *Journal of Pharmaceutical and Biomedical Analysis*, 149, 133–142. <https://doi.org/10.1016/j.jpba.2017.11.011>
- [114] Qiao, Y., Zhao, J., Yue, X., Zhang, Y., et al., (2017). Study on pharmacokinetics and bioequivalence of Vonoprazan pyroglutamate in rats by liquid chromatography with tandem mass spectrometry. *Journal of Chromatography B*, 1059, 56–65. <https://doi.org/10.1016/j.jchromb.2017.05.013>
- [115] Rossmann, J., Schubert, S., Gurke, R., et al., (2014). Simultaneous determination of most prescribed antibiotics in multiple urban wastewater by SPE-LC–MS/MS. *Journal of Chromatography B*, 969, 162–170. <https://doi.org/10.1016/j.jchromb.2014.08.008>
- [116] Saraya, R. E., Hassan, Y. F., Eltukhi, et al., (2022). Ultra-Sensitive Fluorimetric Method for the First Estimation of Vonoprazan in Real Human Plasma and Content Uniformity Test. *Journal of Fluorescence*, 32(5), 1725–1732. <https://doi.org/10.1007/s10895-022-02979-2>
- [117] Smerikarova, M., Bozhanov, S., Maslarska, V. (2019). Development and Validation of a RP-HPLC Method to Quantify Amoxicillin, Tinidazole, Esomeprazole and Lansoprazole in a Mixture. *Indian Journal of Pharmaceutical Sciences*, 81(6). <https://doi.org/10.36468/pharmaceutical-sciences.611>
- [118] Sushma, P., Pawar, A. K. M., Divya, M. (2021). Development of a Validated Stability Indicating Method for Quantification of Amoxicillin, Clarithromycin and Lansoprazole in Bulk and Pharmaceutical Dosage form by RP-HPLC. *Journal of Pharmaceutical Research International*, 207–220. <https://doi.org/10.9734/jpri/2021/v33i45B32798>
- [119] Yoneyama, T., Teshima, K., Jinno, F., et al., (2016). A validated simultaneous quantification method for vonoprazan (TAK-438F) and its 4 metabolites in human plasma by the liquid chromatography-tandem mass spectrometry. *Journal of Chromatography B*, 1015–1016, 42–49. <https://doi.org/10.1016/j.jchromb.2016.01.051>

Publications

International Journals

- [1] Pandya, Y., & Patel, S. (2022). RP-HPLC stability method development & validation for anti-HIV drugs cabotegravir & rilpivirine in I.M. injection and in human plasma. *International Journal of Health Sciences*, 6(S1), 9104–9117.
UGC Care Listed Journal –Group-2 Scopus Source List Scopus Indexed Journal
- [2] Pandya, Y., & Patel, S. (2022). A novel rapid combined RP-HPLC stability method development and validation for antiviral hiv combinations lamivudine, tenofovir, doravirine in dosage form and its application to in vitro dissolution. *International Journal of Health Sciences*, 6(S3), 4931–4949.
UGC Care Listed Journal –Group-2 Scopus Source List Scopus Indexed Journal
- [3] Accepted for Publication in year 2023: Pandya, Y., Patel, S. (2023). A Rapid RP-HPLC Stability Method Development & Validation For Antiviral HIV Drugs Cabotegravir & Rilpivirine In I.M. Injection. *International Journal of Biology, Pharmacy and Allied Sciences IJBPAS*, 12(3).
UGC Care Listed Journal –Group-2 Web of Science- Science citation Indexed Expanded Master Journal Group Listed Journal

International Conferences

- [4] Conference Proceeding Publication: Yogi Pandya., Samixa Patel., (2022). Rapid RP-HPLC Method Development And Validation For Novel Antiviral Drugs In Synthetic Mixtures. In A. Dr. Divyang Vyas., Dr. Ashish Kothari., etal., (Eds.). International Conference On Emerging Trends & Contemporary Practices 2022, Atmiya University, paper Id-117, pp-7.
- [5] A Rapid RP-HPLC Analytical Method For Estimation Of Sofosbuvir & Ledipasvir And Daclatasvir & Simeprevir By Gradient Elution Method In Synthetic Mixtures. e-Conference at LJ University, Ahmadabad Gujarat.
- [6] Analysis Methods For Environmental Waste Management In Pharmaceutical Industries. e-Conference Department of Environmental Science & UGC-

- STRIDE Cell In Collaboration With Brazil Chapter - International Youth Society, Australia.
- [7] Rapid RP-HPLC Analytical Method For Estimation Of Sofosbuvir & Ledipasvir And Daclatasvir & Simeprevir By Gradient Elution Method In Synthetic Mixtures. GUJCOST Sponsored International Conference On : Vital Role Of Polymers In Drug Delivery, at LJ University, Ahmadabad. Gujarat.
- [8] Utilization Of 3d Printing Tool In Pharmaceutical Analysis. GUJCOST & DST sponsored two-day International e-conference on “Revolutionary Applications of 3D-Printing Technology in Pharma and Healthcare System” at Arihant School of Pharmacy & Bioresearch Institute, Adalaj, Gandhinagar. Gujarat.
- [9] Use of Novel Instrumental Analysis Methods for the Antiviral Drugs. GUJCOST Sponsored International e-Conference on: “Regulatory Trends of Biologics and Medical Devices in Covid-19 Pandemic, at LJ University, Ahmadabad. Gujarat.
- [10] Rapid RP-HPLC Method Development And Validation For Novel Antiviral Drugs In Synthetic Mixtures. International Conference On Emerging Trends & Contemporary Practices 2022 Atmiya University, Rajkot, Gujarat.

Books / Book Chapters

- [11] Conference Proceeding Publication: Yogi Pandya., Samixa Patel., (2022). Rapid RP-HPLC Method Development And Validation For Novel Antiviral Drugs In Synthetic Mixtures. In A. Dr. Divyang Vyas., Dr. Ashish Kothari., etal., (Eds.). International Conference On Emerging Trends & Contemporary Practices 2022, Atmiya University, paper Id-117, pp-7.

Patent

- [12] Patent Publication: Formulation And In Vitro Evaluation Of Controlled Release Repaglinide Bilayer Tablets. Official Journal Of The Patent Office, The Publication Of The Patent Office, Issue-26/2022, Dt-1/07/2022, 41267.
- [13] Patent Publication: Chromatographic Analysis of Underutilized Oil Seeds for Future Commercial Development. Official Journal Of The Patent Office, The Publication Of The Patent Office, Issue-36/2022, Dt-09/09/2022, 56261.

- [14] Patent Publication: Canadian Copyright: Pure Erlotinib Quantification By A Trusted HPLC Method. Canadian Intellectual Property Office, Reg. No. 1198020. Dt-25/11/2022.
- [15] Patent Publication: Preparation of Nanocapsules Based on Preformed Polymers. Official Journal Of The Patent Office, The Publication Of The Patent Office, Issue-44/2022, Dt-04/11/2022, 69948.
- [16] Patent Publication: Developing A Drug for Atopic Dermatitis and Allergic Disorders using Crisaborole and Valcosporins. Official Journal Of The Patent Office, The Publication Of The Patent Office, Issue-34/2022, Dt-26/08/2022, 53309.

Journal Publications Under Review Process

- [17] Development of Stability HPLC Method and Validation for Maribavir and its Application to in vitro Dissolution. Journal: International Journal Of Pharmaceutical Education And Research.
- [18] A Combined Novel & Rapid RP-HPLC Stability Method Development & Validation For Hiv Drug Combinations Lamivudine, Tenofovir, Doravirine In Dosage Forms And Its Application To In Vitro Dissolution. Journal: International Journal of Biology, Pharmacy and Allied Sciences IJBPAS.